Evidence map›Paper›PMID 42091863›Full record

ArticleNature communications2026

Alzheimer's Disease blood biomarkers measured through remote capillary sampling correlate with cognition in older adults.

Anne Corbett, Millie Sander-Long, Nicholas J Ashton, Hanna Huber, Jakub Vavra, Luisa Sophie Braun-Wohlfahrt, Henrik Zetterberg, Laia Montoliu-Gaya, Jeffrey Cummings, Freya Bateman and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Anne CorbettUniversity of Exeter Medical School, University of Exeter, Exeter, UK. a.m.j.corbett@exeter.ac.uk.
Millie Sander-LongUniversity of Exeter Medical School, University of Exeter, Exeter, UK.
Nicholas J AshtonDepartment of Psychiatry and Neurochemistry, Institute of Neuroscience & Physiology, the Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden.ORCID 0000-0002-3579-8804
Hanna HuberDepartment of Psychiatry and Neurochemistry, Institute of Neuroscience & Physiology, the Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden.
Jakub VavraDepartment of Psychiatry and Neurochemistry, Institute of Neuroscience & Physiology, the Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden.
Luisa Sophie Braun-WohlfahrtDepartment of Psychiatry and Neurochemistry, Institute of Neuroscience & Physiology, the Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden.ORCID 0009-0007-7845-7851
Henrik ZetterbergDepartment of Psychiatry and Neurochemistry, Institute of Neuroscience & Physiology, the Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden.ORCID 0000-0003-3930-4354
Laia Montoliu-GayaDepartment of Psychiatry and Neurochemistry, Institute of Neuroscience & Physiology, the Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden.ORCID 0000-0001-7684-6318
Jeffrey CummingsChambers-Grundy Center for Transformative Neuroscience, Department of Brain Health, Kirk Kerkorian School of Medicine, University of Nevada Las Vegas, Las Vegas, Nevada, USA.ORCID 0000-0001-8944-4158
Freya BatemanUniversity of Exeter Medical School, University of Exeter, Exeter, UK.ORCID 0000-0002-4329-0912
Christine DavisUniversity of Exeter Medical School, University of Exeter, Exeter, UK.
Clive BallardUniversity of Exeter Medical School, University of Exeter, Exeter, UK.ORCID 0000-0003-0022-5632

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Blood biomarkers are rapidly becoming established for Alzheimer's Disease (AD) diagnosis. However, there is a need for more scalable tools to reach the 99% of individuals with early cognitive impairment who are not seen in specialist healthcare services. A recent study validated a capillary blood sampling technique to detect the p-tau217 and GFAP biomarkers. Here we used our PROTECT research study to show that these biomarkers, when collected using self-administered fingerprick tests, correlate well with venous blood biomarkers and with cognition and function in 174 people who were cognitively normal or who had mild cognitive impairment or AD. They can be used in combination with computerised cognitive testing to identify people with the highest risk of AD. The GFAP biomarker appears to be associated with vascular risk, unlike p-tau217. Patient feedback indicates high acceptability and usability of the capillary test method, giving confidence in the feasibility of this technology. The work suggests that capillary blood biomarkers could be used to enable triage of people with varying levels of risk of AD in clinical practice and for clinical trials, and could be used outside of clinical settings.

Indexed as

Alzheimer DiseaseBiomarkersBlood Specimen CollectionCognitionGlial Fibrillary Acidic ProteinAgedAged, 80 and overCapillariesCognitive DysfunctionFemaleHumansMaletau ProteinsBiomarkersGFAP protein, humanGlial Fibrillary Acidic Proteintau Proteins

Identifiers

PMID42091863
PMCPMC13149973

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.